Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for bone loss prevention in premenopausal women receiving ovarian suppression and aromatase inhibition for breast cancer
ACTRN12616001051437Phase 3Completed
- Sponsor
- Professor Mathis Grossmann
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in osteoporosis and breast cancer comparing Denosumab with Placebo (2 arms). Primary endpoint: Total volumetric bone mineral density at the distal tibia. Started Sep 2016; status: completed.
02
Drugs
denosumab
03
Conditions
osteoporosisbreast cancer
Beyond the preview
Go deeper on ACTRN12616001051437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001051437.